The GLP-1 Boom: A 587% prescription surge that’s redefining weight management
Between 2019 and 2024, prescriptions for GLP-1 receptor agonists, drugs like Ozempic, Semaglutide, and Rybelsus, skyrocketed by an incredible 587%. Once primarily prescribed for type 2 diabetes, these medications are now reshaping the global weight-management landscape. What started as a niche treatment has become a cultural and commercial phenomenon, with real-world data now confirming what the…